William C Manning
Overview
Explore the profile of William C Manning including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
788
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blume J, Manning W, Troiano G, Hornburg D, Figa M, Hesterberg L, et al.
Nat Commun
. 2020 Jul;
11(1):3662.
PMID: 32699280
Large-scale, unbiased proteomics studies are constrained by the complexity of the plasma proteome. Here we report a highly parallel protein quantitation platform integrating nanoparticle (NP) protein coronas with liquid chromatography-mass...
2.
Scott Eastman P, Manning W, Qureshi F, Haney D, Cavet G, Alexander C, et al.
J Pharm Biomed Anal
. 2012 Jul;
70:415-24.
PMID: 22749821
Rheumatoid arthritis (RA) is a chronic inflammatory disorder that primarily involves the joints. Accurate and frequent assessment of RA disease activity is critical to optimal treatment planning. A novel algorithm...
3.
Zhao X, Qureshi F, Scott Eastman P, Manning W, Alexander C, Robinson W, et al.
J Immunol Methods
. 2012 Feb;
378(1-2):72-80.
PMID: 22366959
Variability in pre-analytical blood sampling and handling can significantly impact results obtained in quantitative immunoassays. Understanding the impact of these variables is critical for accurate quantification and validation of biomarker...
4.
Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann O, Ofarrell A, et al.
Blood
. 2004 Oct;
105(3):986-93.
PMID: 15459012
Fifteen patients with refractory AML were treated in a phase 1 study with SU11248, an oral kinase inhibitor of fms-like tyrosine kinase 3 (Flt3), Kit, vascular endothelial growth factor (VEGF),...
5.
Morimoto A, Tan N, West K, McArthur G, Toner G, Manning W, et al.
Oncogene
. 2004 Feb;
23(8):1618-26.
PMID: 14985702
Biomarkers that indicate biological activity and/or efficacy are a potentially useful tool in the development of molecularly targeted therapeutics. It is useful, though challenging, to identify biomarkers during preclinical development...
6.
Sapieha P, Peltier M, Rendahl K, Manning W, Di Polo A
Mol Cell Neurosci
. 2003 Dec;
24(3):656-72.
PMID: 14664816
Basic fibroblast growth factor (or FGF-2) has been shown to be a potent stimulator of retinal ganglion cell (RGC) axonal growth during development. Here we investigated if FGF-2 upregulation in...
7.
Ofarrell A, Foran J, Fiedler W, Serve H, Paquette R, Cooper M, et al.
Clin Cancer Res
. 2003 Dec;
9(15):5465-76.
PMID: 14654525
Purpose: Obtaining direct and rapid proof of molecular activity in early clinical trials is critical for optimal clinical development of novel targeted therapies. SU11248 is an oral multitargeted kinase inhibitor...
8.
DePrimo S, Wong L, Khatry D, Nicholas S, Manning W, Smolich B, et al.
BMC Cancer
. 2003 Mar;
3:3.
PMID: 12657164
Background: Microarray-based gene expression profiling is a powerful approach for the identification of molecular biomarkers of disease, particularly in human cancers. Utility of this approach to measure responses to therapy...
9.
Wang F, Rendahl K, Manning W, Quiroz D, Coyne M, Miller S
Invest Ophthalmol Vis Sci
. 2003 Jan;
44(2):781-90.
PMID: 12556414
Purpose: To develop a small-animal model of choroidal neovascularization (CNV) by injecting adeno-associated virus (AAV)-VEGF into the subretinal space (SRS) of rats. Methods: An adeno-associated viral vector encoding human VEGF(165)...
10.
Ofarrell A, Abrams T, Yuen H, Ngai T, Louie S, Yee K, et al.
Blood
. 2003 Jan;
101(9):3597-605.
PMID: 12531805
FLT3 (fms-related tyrosine kinase/Flk2/Stk-2) is a receptor tyrosine kinase (RTK) primarily expressed on hematopoietic cells. In blasts from acute myelogenous leukemia (AML) patients, 2 classes of FLT3 activating mutations have...